Antibiotherapy applied to uncomplicated urethritis and cervicitis;Traitement antibiotique des urétrites et cervicités non compliquées

Medecine et Maladies Infectieuses

Volumn 36, Issue 1, 2006, Pages 27-35

  Dumarcet, N ^a  

^a NONE

Author keywords

Cervicitis; Chlamydia trachomatis; Neisseria gonorrhoeae; Urethritis

Indexed keywords

AZITHROMYCIN; CEFIXIME; CEFTRIAXONE; CEPHALOSPORIN; CIPROFLOXACIN; DOXYCYCLINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPECTINOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BLOOD EXAMINATION; CHLAMYDIA TRACHOMATIS; CONDOM; DOSE RESPONSE; DRUG TOLERANCE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NEISSERIA GONORRHOEAE; SEXUAL INTERCOURSE; SEXUALLY TRANSMITTED DISEASE; SYPHILIS; URETHRITIS; UTERINE CERVICITIS; VACCINATION;

ANTI-BACTERIAL AGENTS; ASIA; CHLAMYDIA INFECTIONS; CIPROFLOXACIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; FRANCE; GONORRHEA; GREAT BRITAIN; HUMANS; LABORATORIES; MALE; PHARYNGITIS; PROCTITIS; SENTINEL SURVEILLANCE; SEXUAL BEHAVIOR; URETHRITIS; UTERINE CERVICITIS;

EID: 31944434212     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2005.10.009     Document Type: Article

References (30)

1. Tapsall J. Current concepts in the management of gonorrhoea. Expert Opin Pharmacother February 2002;3(2):147-57.
2. Sarwal S, Wong T, Sevigny C, Ng LK. Increasing incidence of ciprofloxacin-resistant Neisseria gonorrhoeae infection in Canada. CMAJ April 2003 1;168(7):872-3.
3. Robert J. Comportement et gestes à risque. In : Morisset R, Pechère JC. Reconnai○tre, comprendre, traiter les MTS. Edisem (Montréal), Maloine (Paris) 1990;519p.
4. Center for Diseases Control. Sexually Transmitted Disease Surveillance 2003 supplement: Gonococcal Isolate Surveillance Project (GISP). Annual report 2003 Atlanta. Division of STD Prevention, 2004.
5. o 17, August 2002:p. 13-15.
6. Ito M, Yasuda M, Yokoi S, Ito S, Takahashi Y, Ishihara S, et al. Remarkable increase in Central Japan in 2001-2002 of Neisseria gonorrhoeae isolates with decreased susceptibility to penicillin, tetracycline, oral cephalosporins, and fluoroquinolones. Antimicrob Agents Chemother August 2004;48(8):3185-7.
7. GRASP-The Gonococcal Resistance to Antimicrobials Surveillance Programme-Annual report-Year 2003 Collection - Rapport 2004-Health Protection Agency - England and Wales.
8. Renewing the focus: HIV and other sexually transmitted infections in the United Kingdom in 2002. An update : November 2003. Health Protection Agency.
9. Arreaza L, Salcedo C, Alcala B, Berron S, Martin E, Vazquez JA. Antibiotic resistance of Neisseria gonorrhoeae in Spain : trends over the last two decades. J Antimicrob Chemother January 2003;51(1):153-6.
10. o 4:209-14.
11. o 15/2004 : les infections à gonocoque en 2001 et 2002 : données du Réseau national des gonocoques (RENAGO).
12. Herida M, Sednaoui P, Laurent E et les biologistes du réseau RENAGO-BEA 2001-2003-Rapport InVS in press.
13. Réseau sentinelles, Inserm U707/U444 : www.sentiweb.org/ documentation/bilans annuels.
14. Ison CA, Martin IM, London gonococcal working group. Gonorrhoea in London: usefulness of first line therapies. Sex Transm Infect April 2002;78(2):106-9.
15. Moran JS, Levine WC. Drugs of choice for the treatment of uncomplicated gonococcal infections. Clin Infect Dis April 1995;20Suppl 1:S47-S65.
16. Clinical Effectiveness Group British Association of Sexual Health and HIV (BASHH). Clinical effectiveness guidelines on the management of gonorrhoea in adults. Site web, publié en 2002, actualisé en 2003-2005 (http://www.bashh.org/guidelines/ceguidelines.htm).
17. Increases in fluoroquinolone-resistant Neisseria gonorrhoeae among men who have sex with men-United States, 2003 and revised Recommendations for Gonorrhea treatment, 2004. MMWR April 2004;53(16):335-38.
18. Dan M. The use of fluoroquinolones in gonorrhoea : the increasing problem of resistance. Expert Opin Pharmacother April 2004;5(4): 829-54.
19. Sexually transmitted diseases-treatment guidelines 2002. MMWR 2002 May 10;51, RR-6.
20. Naber KG, Bergman B, Bishop Mc, Bjerklund-Johansen TE, Botto H, Lobel B, Jimenez-Cruz F, Selvaggi FP, Urinary Tract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU). EAU guidelines for the management of urinary and male genital tract infections. Eur Urol November 2001;40(5):576-88.
21. Horner PJ. European guideline for the management of urethritis. Int J STD AIDS October 2001;12 suppl 3:63-7.
22. World Health Organization 2003 - Guidelines for the management of sexually transmitted infections.
23. Judson FN, Ehret JM, Handsfield HH. Comparative study of ceftriaxone and spectinomycin for treatment of pharyngeal and anorectal gonorrhea. JAMA March 1985 8;253(10):1417-9.
24. Ramus RM, Sheffield JS, Mayfiels JA, Wendel GD Jr. A randomized trial that compared oral cefixime and intramuscular ceftriaxone for the treatment of gonorrhea in pregnancy. Am J Obstet Gynecol September 2001;185(3):629-32.
25. Dan M, Poch F, Sheinberg B. High prevalence of high-level ciprofloxacin resistance in Neisseria gonorrhoeae in Tel Aviv, Israel : correlation with response to therapy. Antimicrob Agents Chemother 2002 Jun;46(6):1671-3.
26. Hunter HH, Dalu ZA, Martin DH, Douglas JM Jr, McCarty JM, Schlosserg D, Azithromycin Gonorrhea Group. Multicenter trial of single-dose azithromycin vs ceftriaxone in the treatment of uncomplicted gonorrhea. Sexually Transmitted Disease March-April 1994;21(2):107-11.
27. Wang SA, Lee MV, O'Connor N, Iverson CJ, Ohye RG, Whiticar PM, Hale JA, Trees DL, Knapp JS, Effler PV, Weinstock HS. Multidrug-resistant Neisseria gonorrhoeae with decreased susceptibility to cefixime-Hawaii, 2001. Clin Infect Dis September 2003 15;37(6):849-52.
28. Place des techniques de biologie moléculaire dans l'identification des infections urogénitales basses à Chlamydia trachomatis - Évaluation du dépistage des infections urogénitales basses à Chlamydia trachomatis en France. Anaes February 2003:Tome 1 & 2.
29. Golden MR, Whittington WL, Handsfield HH, Hughes JP, Stamm WE, Hogben M. Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection. N Engl J Med 2005;352:676-85.
30. World Health Organization Global Strategy for Containment of Antimicrobial Resistance -2001- http://www.who.int/emc.